The global Myasthenia Gravis Disease Drugs market was valued at US$ 1467.3 million in 2022 and is projected to reach US$ 2400 million by 2029, at a CAGR of 7.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
This report aims to provide a comprehensive presentation of the global market for Myasthenia Gravis Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myasthenia Gravis Disease Drugs.
This report contains market size and forecasts of Myasthenia Gravis Disease Drugs in global, including the following market information:
Global Myasthenia Gravis Disease Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.
We surveyed the Myasthenia Gravis Disease Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myasthenia Gravis Disease Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Myasthenia Gravis Disease Drugs Market Segment Percentages, by Type, 2022 (%)
- Acetylcholinesterase Inhibitors
- Immunosuppressant Drugs
- Steroid
- Others
Global Myasthenia Gravis Disease Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Myasthenia Gravis Disease Drugs Market Segment Percentages, by Application, 2022 (%)
Global Myasthenia Gravis Disease Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Myasthenia Gravis Disease Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Myasthenia Gravis Disease Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Myasthenia Gravis Disease Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- GlaxoSmithKline
- Novartis
- Teva Pharmaceutical
- Roche
- Bristol-Myers Squibb
- Apotex
- Cipla
- Biogen
- AbbVie
- Bausch Health
- Sun Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Myasthenia Gravis Disease Drugs, market overview.
Chapter 2: Global Myasthenia Gravis Disease Drugs market size in revenue.
Chapter 3: Detailed analysis of Myasthenia Gravis Disease Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Myasthenia Gravis Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Myasthenia Gravis Disease Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Myasthenia Gravis Disease Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Myasthenia Gravis Disease Drugs Overall Market Size
2.1 Global Myasthenia Gravis Disease Drugs Market Size: 2022 VS 2030
2.2 Global Myasthenia Gravis Disease Drugs Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Myasthenia Gravis Disease Drugs Players in Global Market
3.2 Top Global Myasthenia Gravis Disease Drugs Companies Ranked by Revenue
3.3 Global Myasthenia Gravis Disease Drugs Revenue by Companies
3.4 Top 3 and Top 5 Myasthenia Gravis Disease Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Myasthenia Gravis Disease Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Myasthenia Gravis Disease Drugs Players in Global Market
3.6.1 List of Global Tier 1 Myasthenia Gravis Disease Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Myasthenia Gravis Disease Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Myasthenia Gravis Disease Drugs Market Size Markets, 2022 & 2030
4.1.2 Acetylcholinesterase Inhibitors
4.1.3 Immunosuppressant Drugs
4.1.4 Steroid
4.1.5 Others
4.2 By Type - Global Myasthenia Gravis Disease Drugs Revenue & Forecasts
4.2.1 By Type - Global Myasthenia Gravis Disease Drugs Revenue, 2018-2023
4.2.2 By Type - Global Myasthenia Gravis Disease Drugs Revenue, 2024-2030
4.2.3 By Type - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Myasthenia Gravis Disease Drugs Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Myasthenia Gravis Disease Drugs Revenue & Forecasts
5.2.1 By Application - Global Myasthenia Gravis Disease Drugs Revenue, 2018-2023
5.2.2 By Application - Global Myasthenia Gravis Disease Drugs Revenue, 2024-2030
5.2.3 By Application - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Myasthenia Gravis Disease Drugs Market Size, 2022 & 2030
6.2 By Region - Global Myasthenia Gravis Disease Drugs Revenue & Forecasts
6.2.1 By Region - Global Myasthenia Gravis Disease Drugs Revenue, 2018-2023
6.2.2 By Region - Global Myasthenia Gravis Disease Drugs Revenue, 2024-2030
6.2.3 By Region - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Myasthenia Gravis Disease Drugs Revenue, 2018-2030
6.3.2 US Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.3.3 Canada Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.3.4 Mexico Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Myasthenia Gravis Disease Drugs Revenue, 2018-2030
6.4.2 Germany Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.4.3 France Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.4.4 U.K. Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.4.5 Italy Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.4.6 Russia Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.4.7 Nordic Countries Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.4.8 Benelux Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Myasthenia Gravis Disease Drugs Revenue, 2018-2030
6.5.2 China Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.5.3 Japan Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.5.4 South Korea Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.5.5 Southeast Asia Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.5.6 India Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Myasthenia Gravis Disease Drugs Revenue, 2018-2030
6.6.2 Brazil Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.6.3 Argentina Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue, 2018-2030
6.7.2 Turkey Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.7.3 Israel Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.7.4 Saudi Arabia Myasthenia Gravis Disease Drugs Market Size, 2018-2030
6.7.5 UAE Myasthenia Gravis Disease Drugs Market Size, 2018-2030
7 Myasthenia Gravis Disease Drugs Companies Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Summary
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Myasthenia Gravis Disease Drugs Major Product Offerings
7.1.4 GlaxoSmithKline Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.1.5 GlaxoSmithKline Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Myasthenia Gravis Disease Drugs Major Product Offerings
7.2.4 Novartis Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Teva Pharmaceutical
7.3.1 Teva Pharmaceutical Company Summary
7.3.2 Teva Pharmaceutical Business Overview
7.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Drugs Major Product Offerings
7.3.4 Teva Pharmaceutical Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.3.5 Teva Pharmaceutical Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Myasthenia Gravis Disease Drugs Major Product Offerings
7.4.4 Roche Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Major Product Offerings
7.5.4 Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Apotex
7.6.1 Apotex Company Summary
7.6.2 Apotex Business Overview
7.6.3 Apotex Myasthenia Gravis Disease Drugs Major Product Offerings
7.6.4 Apotex Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.6.5 Apotex Key News & Latest Developments
7.7 Cipla
7.7.1 Cipla Company Summary
7.7.2 Cipla Business Overview
7.7.3 Cipla Myasthenia Gravis Disease Drugs Major Product Offerings
7.7.4 Cipla Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.7.5 Cipla Key News & Latest Developments
7.8 Biogen
7.8.1 Biogen Company Summary
7.8.2 Biogen Business Overview
7.8.3 Biogen Myasthenia Gravis Disease Drugs Major Product Offerings
7.8.4 Biogen Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.8.5 Biogen Key News & Latest Developments
7.9 AbbVie
7.9.1 AbbVie Company Summary
7.9.2 AbbVie Business Overview
7.9.3 AbbVie Myasthenia Gravis Disease Drugs Major Product Offerings
7.9.4 AbbVie Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.9.5 AbbVie Key News & Latest Developments
7.10 Bausch Health
7.10.1 Bausch Health Company Summary
7.10.2 Bausch Health Business Overview
7.10.3 Bausch Health Myasthenia Gravis Disease Drugs Major Product Offerings
7.10.4 Bausch Health Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.10.5 Bausch Health Key News & Latest Developments
7.11 Sun Pharmaceuticals
7.11.1 Sun Pharmaceuticals Company Summary
7.11.2 Sun Pharmaceuticals Business Overview
7.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Major Product Offerings
7.11.4 Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Revenue in Global Market (2018-2023)
7.11.5 Sun Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Myasthenia Gravis Disease Drugs Market Opportunities & Trends in Global Market
Table 2. Myasthenia Gravis Disease Drugs Market Drivers in Global Market
Table 3. Myasthenia Gravis Disease Drugs Market Restraints in Global Market
Table 4. Key Players of Myasthenia Gravis Disease Drugs in Global Market
Table 5. Top Myasthenia Gravis Disease Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Myasthenia Gravis Disease Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Myasthenia Gravis Disease Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Myasthenia Gravis Disease Drugs Product Type
Table 9. List of Global Tier 1 Myasthenia Gravis Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Myasthenia Gravis Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Myasthenia Gravis Disease Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Myasthenia Gravis Disease Drugs Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2024-2030
Table 30. GlaxoSmithKline Company Summary
Table 31. GlaxoSmithKline Myasthenia Gravis Disease Drugs Product Offerings
Table 32. GlaxoSmithKline Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. GlaxoSmithKline Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis Myasthenia Gravis Disease Drugs Product Offerings
Table 36. Novartis Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis Key News & Latest Developments
Table 38. Teva Pharmaceutical Company Summary
Table 39. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Product Offerings
Table 40. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Teva Pharmaceutical Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Myasthenia Gravis Disease Drugs Product Offerings
Table 44. Roche Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Roche Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company Summary
Table 47. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Product Offerings
Table 48. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Bristol-Myers Squibb Key News & Latest Developments
Table 50. Apotex Company Summary
Table 51. Apotex Myasthenia Gravis Disease Drugs Product Offerings
Table 52. Apotex Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Apotex Key News & Latest Developments
Table 54. Cipla Company Summary
Table 55. Cipla Myasthenia Gravis Disease Drugs Product Offerings
Table 56. Cipla Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Cipla Key News & Latest Developments
Table 58. Biogen Company Summary
Table 59. Biogen Myasthenia Gravis Disease Drugs Product Offerings
Table 60. Biogen Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Biogen Key News & Latest Developments
Table 62. AbbVie Company Summary
Table 63. AbbVie Myasthenia Gravis Disease Drugs Product Offerings
Table 64. AbbVie Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. AbbVie Key News & Latest Developments
Table 66. Bausch Health Company Summary
Table 67. Bausch Health Myasthenia Gravis Disease Drugs Product Offerings
Table 68. Bausch Health Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Bausch Health Key News & Latest Developments
Table 70. Sun Pharmaceuticals Company Summary
Table 71. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Product Offerings
Table 72. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Sun Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Myasthenia Gravis Disease Drugs Segment by Type in 2022
Figure 2. Myasthenia Gravis Disease Drugs Segment by Application in 2022
Figure 3. Global Myasthenia Gravis Disease Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Myasthenia Gravis Disease Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Myasthenia Gravis Disease Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Myasthenia Gravis Disease Drugs Revenue in 2022
Figure 8. By Type - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 9. By Application - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 10. By Type - Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 12. By Application - Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 14. By Region - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 15. By Country - North America Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 16. US Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 20. Germany Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 21. France Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 28. China Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. India Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 34. Brazil Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue Market Share, 2018-2030
Figure 37. Turkey Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. GlaxoSmithKline Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Roche Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Apotex Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Cipla Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Biogen Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. AbbVie Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Bausch Health Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
